Markets SVB Leerink starts AN2 Therapeutics at OP; PT $27 SVB Leerink launched coverage of AN2 Therapeutics (NASDAQ:ANTX) with an “outperform” rating and price target of $27. The stock closed at $14.79 on April 18. AN2 is a clinical-stage biotech company developing therapies... April 19, 2022